Acquired non-type 1 diabetes in childhood: Subtypes, diagnosis, and management

Archives of Disease in Childhood

Volumn 89, Issue 12, 2004, Pages 1138-1144

  Porter, J R ^a   Barrett, T G ^a  

^a BIRMINGHAM CHILDREN S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; GLUCOSE; INSULIN; INSULIN SENSITIZING AGENT; METFORMIN;

ALGORITHM; ALSTROM SYNDROME; AUTOIMMUNE DISEASE; BARDET BIEDL SYNDROME; CHILD; CHILDHOOD DISEASE; CYSTIC FIBROSIS; DIABETES MELLITUS; DOWN SYNDROME; GLUCOSE BLOOD LEVEL; HUMAN; IATROGENIC DISEASE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RESISTANCE; KETONURIA; MATURITY ONSET DIABETES MELLITUS; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; OVARY POLYCYSTIC DISEASE; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; REVIEW; THALASSEMIA; WEIGHT REDUCTION; WOLFRAM SYNDROME; WORLD HEALTH ORGANIZATION;

CHILD; DIABETES COMPLICATIONS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; DIAGNOSIS, DIFFERENTIAL; HUMANS; INSULIN RESISTANCE;

EID: 9644257222     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2003.036608     Document Type: Review

References (79)

1. Sperling M. Diabetes mellitus. In: Waldo N, eds. Nelson textbook of paediatrics. W.B. Sounders Company, 1996:1647.
2. World Health Organisation. Definition, diagnosis and classification of diabetes mellitus and its complications. Geneva: World Health Organisation, 1999.
3. Temple IK, Shield JP. Transient neonatal diabetes, a disorder of imprinting. J Med Genet 2002;39:872-5.
4. Barrert TG, Bundey S, Macleod S. Neurodegeneration and diabetes: UK nationwide study of Wolfram (DIDMOAD) syndrome. Lancet 1995;346:1458-63.
5. Hattersley AT, Turner RC, Permutt MA, et al. Linkage of type 2 diabetes to the glucokinase gene. Lancet 1992;339:1307-10.
6. Al-Uzri A, Stablein D, Cohn R. Posttransplant diabetes mellitus in pediatric renal transplant recipients: a report of the North American pediatric renal transplant cooperative study (NAPRTCS). Transplantation 2001;72:1020-4.
7. Ehtisham S, Barrett TG, Shaw NJ. Type 2 diabetes mellitus in UK children - an emerging problem. Diabet Med 2000;17:867-71.
8. Ehtisham S, Hattersley AT, Dunger DB, et al. First UK survey of paediatric type 2 diabetes and MODY. Arch Dis Child 2004;89:526-9.
9. Fagot-Campagna A, Pettitt DJ, Engelgau MM, et al. Type 2 diabetes among North American children and adolescents: an epidemiological review and public health perspective. J Pediatr 2000;136:664-72.
10. Reilly JJ, Dorosty AR. Epidemic of obesity in UK children. Lancet 1999;354:1874-5.
11. Muhammad BJ, Swift PG, Raymond NT, et al. Partial remission phase of diabetes in children younger than age 10 years. Arch Dis Child 1999;80:367-9.
12. Seissler J, de Sonnaville JJ, Morgenthaler NG, et al. Immunological heterogeneity in type 1 diabetes: presence of distinct autoantibody patterns in patients with acute onset and slowly progressive disease. Diabetologia 1998;41:891-7.
13. Borg H, Marcus C, Fernlund P, et al. Islet cell antibody frequency differs from that of glutamic acid decarboxylase antibodies/IA2 antibodies after diagnosis of diabetes. Acta Paediatr 2000;89:46-51.
14. Fida S, Myers M, Mackay IC et al. Antibodies to diabetes-associated autoantigens in Indian patients with type 1 diabetes: prevalence of anti-ICA512/IA2 and anti-SOX13. Diabetes Res Clin Pract 2001;52:205-11.
15. Umpierrez G, et al. Immunogenetic analysis suggests different pathogenesis for obese and lean African-Americans with diabetic ketoacidosis. Diabetes Care 1999;22:1517-23.
16. Batstra M, Petersen JS, Bruining GJ, et al. Low prevalence of GAD and IA-2 antibodies in schoolchildren from a village in the Southwestern section of the Netherlands. Hum Immunol 2001;62:1106-10.
17. American Diabetes Association. Type 2 diabetes in children and adolescents. Diabetes Care 2000;23:381-9.
18. Williams CL, Haynam LL, Daniels SR, et al. Cardiovascular health in childhood: A Statement for Health Professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation 2002;106:143-60.
19. Drake AJ, Smith A, Betts PR, et al. Type 2 diabetes in obese white children. Arch Dis Child 2002;86:207-8.
20. Cole TJ, Bellizi MC, Flegal KM, et al. Establishing a standard definition for child overweight and obesity worldwide: international survey. BMJ 2000;320:1-6.
21. Arslanian S. Type 2 diabetes in children: clinical aspects and risk factors. Horm Res 2002;57(suppl 1):19-28.
22. Tarn C, Landin-Olsson M, Ostman J, et al. Glutamic acid decarboxylase antibodies (GADA) is the most important factor for prediction of insulin therapy within 3 years in young adult diabetic patients not classified as type 1 diabetes on clinical grounds. Diabetes Metab Res Rev 2000;16:442-7.
23. Office of National Statistics. Census report 2001, ONS, 2001.
24. Wilkin TJ, Metcalf BS, Murphy MJ, et al. The relative contributions of birth weight, weight change, and current weight to insulin resistance in contemporary 5-year-olds: the EarlyBird Study. Diabetes 2002;51:3468-72.
25. Whincup PH, Gilg JA, Papacosta O, et al. Early evidence of ethnic differences in cardiovascular risk: cross sectional comparison of British South Asian and white children. BMJ 2002;324:635-40.
26. Henricsson M, Nystrom L, Blohme G, et al. The incidence of retinopathy 10 years after diagnosis in young adult people with diabetes: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care 2003;26:349-54.
27. Svensson M, Sundkvist G, Arnqvist HJ, et al. Signs of nephropathy may occur early in young adults with diabetes despite modern diabetes management: results from the nationwide population-based Diabetes Incidence Study in Sweden (DISS). Diabetes Care 2003;26:2903-9.
28. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-12.
29. Jones KL, Arslanian S, Peterokova VA, et al. Effect of metformin in pediatric patients with type 2 diabetes: a randomized controlled trial. Diabetes Care 2002;25:89-94.
30. Tattersall RB, Fajans SS. A difference between the inheritance of classical juvenile-onset and maturity-onset type diabetes of young people. Diabetes 1975;24:44-53.
31. Fajans SS, Bell GI, Polonsky KS. Molecular mechanisms and clinical pathophysiology of maturity-onset diabetes of the young. N Engl J Med 2001;345:971-80.
32. Edlund H. Transcribing pancreas. Diabetes 1998;47:1817-23.
33. Frayling TM, Evans JC, Bulman MP, et al. Beta-cell genes and diabetes: molecular and clinical characterization of mutations in transcription factors. Diabetes 2001;50(suppl 1):94-100.
34. Stride A, Hattersley AT. Different genes, different diabetes: lessons from maturity-onset diabetes of the young. Ann Med 2002;34:207-16.
35. Njolstad PR, Sovik O, Cuesta-Munoz A, et al. Neonatal diabetes mellitus due to complete glucokinase deficiency. N Engl J Med 2001;344:1588-92.
36. Klupa T, Warram JH, Antonellis A, et al. Determinants of the development of diabetes (maturity-onset diabetes of the young-3) in carriers of HNF-1alpha mutations: evidence for parent-of-origin effect. Diabetes Care 2002;25:2292-301.
37. Stride A, Shepherd M, Frayling TM, et al. Intrauterine hyperglycemic is associated with an earlier diagnosis of diabetes in HNF-1 gene mutation carriers. Diabetes Care 2002;25:2287-91.
38. Pearson ER, Liddell WG, Shepherd M, et al. Sensitivity to sulphonylureas in patients with hepatocyte nuclear factor-1alpha gene mutations: evidence for pharmacogenetics in diabetes. Diabet Med 2000;17:543-5.
39. Bingham C, Ellard S, Allen L, et al. Abnormal nephron development associated with a frameshift mutation in the transcription factor hepatocyte nuclear factor-1 beta. Kidney Int 2000;57:898-907.
40. Umpaichitra V, Banerji MA, Castells S. Autoantibodies in children with type 2 diabetes mellitus. J Pediatr Endocrinol Metab 2002;15(suppl 1):525-30.
41. Mackie AD, Thornton SJ, Edenborough FP. Cystic fibrosis-related diabetes. Diabet Med 2003;20:425-37.
42. Hardin DS, LeBlanc A, Para L, et al. Hepatic insulin resistance and defects in substrate utilization in cystic fibrosis. Diabetes 1999;48:1082-7,
43. Hardin DS, LeBlanc A, Lukenbough S, et al. Insulin resistance is associated with decreased clinical status in cystic fibrosis. J Pediatr 1997;130:948-56.
44. Moran A, Hardin D, Rodman D, et al. Diagnosis, screening and management of cystic fibrosis related diabetes mellitus: a consensus conference report. Diabetes Res Clin Pract 1999;45:61-73.
45. Lanng S, Thorsteinsson B, Nerup J, et al. Glucose tolerance in patients with cystic fibrosis: five year prospective study. BMJ 1995;311:655-9.
46. Sullivan MM, Denning CR. Diabetic microangiopathy in patients with cystic fibrosis. Pediatrics 1989;84:642-7.
47. Rolon MA, et al. Cystic fibrosis-related diabetes mellitus: clinical impact of prediabetes and effects of insulin therapy. Acta Paediatr 2001;90:860-7.
48. Anwar AJ, Walker JD, Frier BM. Type 1 diabetes mellitus and Down's syndrome: prevalence, management and diabetic complications. Diabet Med 1998;15:160-3.
49. Van Goor JC, Massa GG, Hirasing R. Increased incidence and prevalence of diabetes mellitus in Down's syndrome. Arch Dis Child 1997;77:186.
50. Shield J. Type 1 diabetes and other autoimmune disorders in Down's syndrome, Down's Syndrome Medical Interest Group (www.dsmig.org.uk), 2001.
51. Homburg R. What is polycystic ovarian syndrome? A proposal for a consensus on the definition and diagnosis of polycystic ovarian syndrome. Hum Reprod 2002;17:2495-9.
52. Pfeifer SM, Dayal M. Treatment of the adolescent patient with polycystic ovary syndrome. Obstet Gynecol Clin North Am 2003;30:337-52.
53. Ibanez L, Ferrer A, Ong K, et al. Insulin sensitization early after menarche prevents progression from precocious pubarche to polycystic ovary syndrome. J Pediatr 2004;144:23-9.
54. Longo N, Wang Y, Smith SA, et al. Genotype-phenotype correlation in inherited severe insulin resistance. Hum Mol Genet 2002;11:1465-75.
55. Glaser NS. Non-insulin-dependent diabetes mellitus in childhood and adolescence. Pediatr Clin North Am 1997;44:307-37.
56. Tritos NA, Mantzoros CS. Clinical review 97: syndromes of severe insulin resistance. J Clin Endocrinol Metab 1998;83:3025-30.
57. Rique S, Ibanez L, Marcos MV, et al. Effects of metformin on androgens and insulin concentrations in type A insulin resistance syndrome. Diabetologia 2000;43:385-6.
58. Bin-Abbas B, Al-Muhim A, Al-Ashwal A. Wolcott-Rallison syndrome in two siblings with isolated central hypothyroidism. Am J Hum Genet 2002;111:187-90.
59. Delepine M, Nicolino M, Barrett T, et al. EIF2AK3, encoding translation initiation factor 2-alpha kinase 3, is mutated in patients with Wolcott-Rallison syndrome. Nat Genet 2000;25:406-9.
60. Khanim F, Kirk J, Latif F, et al. WFS1/Wolframin mutations, Wolfram syndrome and associated diseases. Hum Mutat 2001;17:357-67.
61. Strom T, Hortnagel K, Hofmann S, et al. Diabetes insipidus, diabetes mellitus, optic atrophy and deafness (DIDMOAD) caused by mutations in a novel gene (wolframin) coding for a predicted transmembrane protein. Hum Molec Genet 1998;7:2021-8.
62. Russell-Eggift IM, Clayton PT, Coffey R, et al. Alstrom syndrome. Report of 22 cases and literature review. Ophthalmology 1998;105:1274-80.
63. Satman I, Yilmaz MT, Gursoy N, et al. Evaluation of insulin resistant diabetes mellitus in Alstrom syndrome: a long-term prospective follow-up of three siblings. Diabetes Res Clin Pract 2002;56:189-96.
64. Green JS, Parfrey PS, Harnett JD, et al. The cardinal manifestations of Bardet-Biedl syndrome, a form of Laurence-Moon-Biedl syndrome. N Engl J Med 1989;321:1002-9.
65. Badano JL, Ansley SJ, Leitch CC, et al. Identification of a novel Bardet-Biedl syndrome protein, BBS7, that shores structural features with BBS1 and BBS2. Am J Hum Genet 2003;72:650-8.
66. Badano JL, Kim JC, Haskins BE, et al. Heterozygous mutations in BBS1, BBS2 and BBS6 have a potential epistatic effect on Bardet-Biedl patients with two mutations at a second BBS locus. Hum Molec Genet 2003;12:1651-9.
67. Ozdemir M, Akcakus M, Kurtoglu S, et al. TRMA syndrome (thiamine responsive megaloblastic anemia): a case report and review of the literature. Pediatr Diabetes 2002;3:205-9.
68. Labay V, Raz T, Baron D, et al. Mutations in SLC19A2 cause thiamine-responsive megaloblastic anaemia associated with diabetes mellitus and deafness. Nat Genet 1999;22:300-4.
69. van den Ouweland JM, Lemkes HH, Ruitenbeek W, et al. Mutation in mitochondrial tRNA(Leu)(UUR) gene in a large pedigree with maternally transmitted type II diabetes mellitus and deafness. Nat Genet 1992;1:368-71.
70. Alcolado J, Laji K, Gill-Randall R. Maternal transmission of diabetes. Diabet Med 2002;19:89-98.
71. Zuppinger K, Molinari B, Hirt A, et al. Increased risk of diabetes mellitus in beta-thalassemia major due to iron overload. Helvetica Paediatrica Acta 1979;34:197-207.
72. Dmochowski K, Finegood DT, Francombe W, et al. Factors determining glucose tolerance in patients with thalassemia major. J Clin Endocrinol Metab 1993;77:478-83.
73. Merkel PA, Simonson DC, Amiel SA, et al. Insulin resistance and hyperinsulinemia in patients with thalassemia major treated by hypertransfusion. N Engl J Med 1988;318:809-14.
74. Taskinen M, Saarinen-Pihkala UM, Hovi L, et al. Impaired glucose tolerance and dyslipidaemia as late effects after bone-marrow transplantation in childhood. Lancet 2000;356:993-7.
75. Paolillo J, Boyle GJ, Law YM, et al. Posttransplant diabetes mellitus in pediatric thoracic organ recipients receiving tacrolimus based immunosuppression. Transplantation 2001;71:252-6.
76. Ferner RE. Drug-induced diabetes. In: Alberti KGMM, eds. Bailliere's clinical endocrinology and metabolism. London: W. B. Sounders, 1992:849-66.
77. Feldman-Biliard S, Lissak B, Benrabah R, et al. Intravenous pulse methylprednisolone therapy in eye disease: effect on glucose tolerance. Ophthalmology 2003;110:2369-71.
78. Henriksen JE, Alford F, Ward GM, et al. Risk and mechanism of dexamethasone-induced deterioration of glucose tolerance in non-diabetic first-degree relatives of NIDDM patients. Diabetologia 1997;40:1439-48.
79. Gloyn AL, Pearson ER, Antcliff JF, et al. Activating mutations in the gene encoding the ATP-sensitive potassium channel subunit Kir 6.2 and permanent neonatal diabetes. N Engl J Med 2004;350:1838-49.